NEWARK, N.J., April 26, 2012 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science technology based company, announced today changes to its Board of Directors and management team. Mark Lowenthal is newly appointed to the Board of Directors. Ron Del Mauro has stepped down from the Board for personal reasons. BioNeutral is grateful for Mr. Del Mauro's hard work and significant contributions while serving with the Company and hopes to continue our relationship with him. In addition to joining the Company as a director, the Company expects that Mr. Lowenthal will be an active member of the Company's Management team.
Mr. Lowenthal was previously, amongst other things, President of Revlon Europe, Asia and the Middle East. Mr. Lowenthal stated: "BioNeutral represents a major business opportunity primarily because of its unique product platforms. BioNeutral's products offer a high degree of competitive leverage upon which we can grow the business on a global basis."
Dr. Andy Kielbania stated: "We are pleased to have the seasoned executive experience of Mark Lowenthal. His proven experience in business planning, implementation and development will greatly accelerate our business efforts in health care, consumer goods, industry and the government."
About BioNeutral Group, Inc.
Headquartered in Morristown, New Jersey with lab facilities at the New Jersey Institute of Technology in Newark, Inc., is a specialty technology-based life-science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.
SOURCE BioNeutral Group, Inc.